1898 / 2894
33. Cook TL, Beppu WJ, Hitt BA, et al: Renal effects and
metabolism of sevoflurane in Fischer 344 rats. Anes-
thesiology 43:70, 1975.
34. Ghoneim MM, Pandya HB, Kelley SE, et al: Binding
of thiopental to plasma proteins: Effects on distribu-
tion in the brain and heart. Anesthesiology 45:635,
1976.
35. Burch PG, Stanski DR: Decreased protein binding
and thiopental kinetics. Clin Pharmacol Ther 32:212,
1982.
36. Hudson RJ, Stanski DR, Burch PG: Pharmacokinetics
of methohexital and thiopental in surgical patients.
Anesthesiology 59:215, 1983.
37. Masuda A, Asahi T, Sakamaki M, et al: Uric acid excre-
tion increases during propofol anesthesia. Anesth
Analg 85:144-148, 1997.
38. Thomas JL, Holmes JH: Effect of hemodialysis on
plasma cholinesterase. Anesth Analg 49:323, 1970.
39. Ryan DW: Preoperative serum cholinesterase concen-
tration in chronic renal failure. Br J Anaesth 49:945,
1977.
40. Gronert GA, Theye RA: Pathophysiology of hyperka-
lemia induced by succinylcholine. Anesthesiology
43:89, 1975.
41. Sheiner LB, Stanski DR, Vozek S, et al: Simultaneous
modeling of phamacokinetics and pharmacodynamics:
Application to d-tubocurarine. Clin Pharmacol Ther
25:358, 1979.
42. Gibaldi M, Levy G, Hayton WL: Tubocurarine and
renal failure. Br J Anaesth 44:163, 1972.
43. Stanski DR, Watkins WD: Drugs Disposition in Anes-
thesia. Orlando, FL, Grune & Stratton, 1982.
44. McLeod K, Watson MJ, Rawlins MD: Pharmacokine-
tics of pancuronium in patients with normal and
impaired renal function. Br J Anaesth 48:341, 1976.
45. Hughes R, Chapple DJ: The pharmacology of atracu-
rium: A new competitive neuromuscular blocking
agent. Br J Anaesth 53:31, 1981.
46. Fisher DM: (Almost) everything you learned about
pharmacokinetics was (somewhat) wrong. Anesth
Analg 83:901–903, 1996.
47. Lynam DP, Cronnelly R, Castagnoli KP, et al: The
pharmacodynamics and pharmacokinetics of vecuro-
nium in patients anesthetized with isoflurane with
normal renal function or with renal failure. Anesthe-
siology 69:227, 1988.
48. Gramstad L, Gjerlow JA, Hysing ES, Rugstad HE: Inte-
raction of cyclosporin and its solvent, Cremophor,
with atracurium and vecuronium: Studies in the cat.
Br J Anaesth 58:1149, 1986.
49. Cook DR, Freeman JA, Lai AA, et al: Pharmacokine-
tics of mivacurium in normal patients and in those
with hepatic or renal failure. Br J Anaesth 69:580,
1992.
50. Phillips BJ, Hunter JM: Use of mivacurium chloride
by constant infusion in the anephric patient. Br J
Anaesth 69:492, 1992.
51. Szenohradsky J, Fisher DM, Segredo V, et al: Pharma-
cokinetics of rocuronium bromide (ORG 9426) in
patients with normal renal function or patients
undergoing cadaver renal transplantation. Anesthe-
siology 77:899, 1992.
52. Cronnelly R, Stanski DR, Miller RD, et al: Renal
function and the pharmacokinetics of neostigmine in
anesthetized man. Anesthesiology 51:222, 1979.
53. Cronnelly R, Stanski DR, Miller RD, et al: Pyridostig-
mine kinetics with and without renal function. Clin
Pharmacol Ther 28:78, 1980.
54. Morris RB, Cronnelly R, Miller RD, et al: Pharmaco-
kinetics of edrophonium in anephric and renal trans-
plant patients. Br J Anaesth 53:1311, 1981.
55. Beermann B, Groschineky-Grind M, Rosen A:
Absorption, metabolism and excretion of hydrochlo-
rothiazide. Clin Pharmacol Ther 19:531, 1976.
56. Smith DE, Brater DC, Lin ET, et al: Attenuation of
furosemide diuretic effect by indomethacin: Pharma-
cokinetics evaluation. J Pharmacokinet Biopharm
7:265, 1979.
57. Kornhauser DM, Wood AJJ, Vesta RE, et al: Biological
determinants of propranolol disposition in man. Clin
Pharmacol Ther 23:165, 1978.
58. Henry PD: Comparative pharmacology of calcium
antagonists: Nifedipine, verapamil and diltiazem. Am
J Cardiol 46:1047, 1980.
59. Neurath GB, Dunger M: Blood levels of the metabo-
lites of glyceryl trinitrate and pentaerythritol tetrani-
trate after administration of a two-step preparation.
Arzneimittelforschung 27:416, 1977.
60. Smith RP: Cyanate and thiocyanate: Acute toxicity.
Proc Soc Exp Biol Med 142:1041, 1973.
61. Talseth T: Studies on hydralazine. III: Bioavailability
of hydralazine in man. Eur J Clin Pharmacol 10:395,
1976.
62. Talseth T: Studies on hydralazine. II: Elimination
rate and steady state concentration in patients with
impaired renal function. Eur J Clin Pharmacol
10:311–317, 1976.
63. Luke DR, Awni WM, Halstemson CE, et al:
Bioavailabilty of labetalol in patients with
end-stage renal disease. Ther Drug Monit 14:203–208,
1992.
64. Wiest D: Esmolol: A review of its therapeutic efficacy
and pharmacokinetic characteristics. Clin Pharmaco-
kinet 28:190–202, 1995.
65. ClarksonMR, Friedewald JJ, Eustace JA: Acute kidney
injury. In Brenner BM (ed): Brenner and Rector’s The
Kidney, 8th ed. Philadelphia, WB Saunders, 2008, pp
943–986.
66. Goldman L, Bennett JC (eds): Cecil Textbook of
Medicine, 21st ed. Philadelphia, WB Saunders, 2000,
pp 567–571.
67. Brown CB, Cameron JS, Ogg CS, et al: Established
acute renal failure following surgical operations. In
Friedman EA, Eliahue HE (eds): Proceedings of the
Conference on Acute Renal Failure. DHEW Publica-
tionNo. (NIH) 74-608.Washington, DC, Government
Printing Office, 1973, pp 187.
68. Kolf WJ, Berk HTJ: Artificial kidney dialyzer with
great area. Acta Med Scand 117:121, 1944.
68a.Bromage PR, Gertel M: Brachial plexus anesthesia in
chronic renal failure. Anesthesiology 36:488–493,
1972.
68b.Martin R, Beauregard MD, Tetrault MD: Brachial
plexus block and chronic renal failure. Anesthesiology
69:405–408, 1988.
69. Bellomo R, Chapman M, Finfer S, et al: Low-dose
dopamine in patients with early renal dysfunction: A
placebo-controlled
randomized
trial.
Lancet
356:2139–2143, 2000.
70. Friedrich JO, Adhikari N, Herridge MS,
Beyene J: Meta-analysis: Low-dose dopamine increa-
ses urine output but does not prevent renal dys-
function or death. Ann Intern Med 142:510–524,
2005.
71. Landoni G, Biondi-Zoccai GG, Tumlin JA, et al: Bene-
ficial impact of fenoldopam in critically ill patients
with or at risk for acute renal failure: A meta-analysis
of randomized clinical trials. Am J Kidney Dis 49:56–
68, 2007.
72. Ho KM, Sheridan DJ: Meta-analysis of furosemide to
prevent or treat acute renal failure. BMJ 333:420,
2006.
73. Pannu N, Wiebe N, Tonelli M: Prophylaxis strategies
for contrast-induced nephropathy. JAMA 295:2765–
2779, 2006.
74. Azar I: Transurethral resection of prostate. In Malho-
tra V (ed): Anesthesia for Renal and Genitourinary
Surgery. New York, McGraw-Hill, 1996, pp 93–109.
75. Hatch PD: Surgical and anaesthetic considerations in
transurethral resection of the prostate. Anaesth Inten-
sive Care 15:203–211, 1987.
76. Malhotra V: Transurethral resection of the prostate.
Anesthesiol Clin North Am 18:883–897, 2000.
77. Mebust WK, Holtgreive HL, Cockett AT, Peters PC:
Transurethral prostatectomy—immediate and posto-
perative complications: A cooperative study of 13
participating institutions evaluating 3,885 patients. J
Urol 141:243–247, 1989.
78. Beers RA, Kane PB, Nsouli I, Krauss D: Does a
mid-lumbar block level provide adequate anaesthesia
for transurethral prostatectomy? Can J Anaesth
41:807, 1994.
79. Malhotra V, Perlmutter A: Caudal anesthesia provides
effective anesthesia for laser prostatectomy. Reg
Anesth 22:93, 1997.
80. Blake DW: The general vs. regional anesthesia debate:
Time to re-examine the goals. Aust N Z J Surg 65:51–
56, 1995.
81. Bernstein S, Malhotra V: Regional anesthesia for geni-
tourinary surgery. In Malhotra V (ed): Anesthesia for
Renal Genitourinary Surgery. New York, McGraw-
Hill, 1996, pp 265.
82. Bowman GW, Hoerth JW, McGlotheen JS, et al: Anes-
thesia for transurethral resection of prostate: Spinal
or general? J Am Assoc Nurse Anesth 49:63–68,
1981.
83. Burrows R: Anesthesia for prostatectomies. Anesth
Analg 3:228–237, 1924.
84. Cullen DJ, Apolone G, Greenfield S, et al: ASA physi-
cal status and age predict morbidity after three surgi-
cal procedures. Ann Surg 220:3, 1994.
85. Ashton CM, Lahart CJ, Wray NP: The incidence
perioperative myocardial infarction with transure-
thral resection of the prostate. J Am Geriatr Soc
37:614, 1989.
86. Chung FF, Chung A, Meirer RH, et al: Comparison of
perioperative mental function after general anesthesia
and spinal anaesthesia with intravenous sedation. Can
J Anaesth 36:382–387, 1989.
87. Attalah MM, Hoeft A, El-Ghouri MA, et al: Does
spinal anesthesia affect cerebral oxygenation during
transurethral prostatectomy? Reg Anesth Pain Med
23:119, 1998.
88. Hahn RG: The transurethral resection syndrome—
not yet a finished story. Reg Anesth Pain Med 23:115–
118, 1998.
89. Gravenstein D: Transurethral resection of prostate
(TURP) syndrome: A review of pathophysiology and
management. Anesth Analg 84:438–446, 1997.
90. Asheim GM: Hyponatremia during transurethral
surgery. Can Anaesth Soc J 20:274–280, 1973.
91. Ovassapian A, Joshi CW, Brunner EA: Visual distur-
bance: An unusual symptom of transurethral prosta-
tic resection reaction. Anesthesiology 57:332–334,
1982.
92. Hahn RG, Essen P: ECG and cardiac enzymes after
glycine absorption in transurethral prostatic resec-
tion. Acta Anaesthesiol Scand 38:550, 1994.
93. Hoekstra PT, Kahnoski R, McCamish MA, et al: Tran-
surethral prostatic resection syndrome—a new pers-
pective:
Encephalopathy
with
associated
hyperammonemia. J Urol 130:704–707, 1983.
94. RoeschRP,StoeltingRK,LingemanJE,
etal:Ammoniatoxicity resulting from glycine absorption during
transurethral resection of the prostate. Anesthesio-
logy 58:577–579, 1983.
95. Kenyon HR: Perforations in transurethral opera-
tions: Technic for immediate diagnosis and manage-
ment of extravasations. JAMA 142:798–802, 1950.
96. Holtgrewe HL, Valk WL: Factors influencing the mor-
tality and morbidity of transurethral prostatectomy:
A study of 2015 cases. J Urol 87:450–459, 1962.
1898
Anestesia por subespecialidades en el adulto
IV